Melanoma treatment in Sheffield is delivered through a coordinated specialist service focused on accurate diagnosis, multimodal therapies and long-term follow-up. This guide outlines the typical structure of a dedicated melanoma treatment centre, the roles of surgeons, medical oncologists, dermatopathologists and specialist nurses, and the standard investigations used in staging and surveillance. It also explains how patients are referred, what to expect at clinic appointments, and how the centre supports care planning and recurrence monitoring over time.
What defines a specialist melanoma treatment centre
A specialist melanoma treatment centre in a major city such as Sheffield typically brings together a multidisciplinary team with expertise in surgical and systemic melanoma care. Core characteristics include a dedicated multidisciplinary team that meets regularly to review complex cases, access to comprehensive diagnostic pathology and imaging services, and coordinated follow-up pathways for surveillance and supportive care. These centres emphasise evidence-based treatment according to national guidelines, offer clinical trials when applicable, and provide patient education and psychosocial support as part of a holistic approach.
Multidisciplinary team roles
Effective melanoma care depends on close collaboration between clinicians with different specialties. Key roles usually include:
- Dermatologists and dermat surgeons for initial lesion assessment and Mohs or wide local excision when indicated.
- Histopathologists with dermatopathology interest for accurate tumour reporting and biomarker testing.
- Medical oncologists specialising in melanoma for systemic therapy decisions.
- Specialist nurses who coordinate appointments, education and symptom review.
- Radiologists and, when needed, surgeons in oncology or plastic surgery for complex resections.
Common services and specialties offered
A dedicated melanoma treatment centre in Sheffield typically provides a range of services aligned with best practice, from initial diagnosis through to survivorship and palliative care. Services may include specialised dermatology clinics, pathology with immunohistochemistry and molecular testing, imaging review for staging and response assessment, surgical oncology input for nodal or complex cutaneous disease, and systemic therapy clinics for targeted and immunotherapy options. Supportive services such as lymphoedema care, psychological support and survivorship programmes are also important components.
Key service areas
| Service area | What it involves | Why it matters |
|---|---|---|
| Diagnostic pathology | Clinical assessment, dermatoscopy, biopsy, histopathology, IHC and molecular profiling | Confirms diagnosis, subtype and targetable alterations |
| Staging and imaging | Physical examination, sentinel lymph node biopsy where indicated, CT/MRI for advanced disease | Determines extent of disease and guides treatment choice |
| Surgical management | Wide local excision, lymph node procedures, complex wound care | Removes or controls local and regional disease |
| Systemic therapies | Immunotherapy, targeted therapy, chemotherapy and clinical trial options | Treats advanced disease and reduces recurrence risk where applicable |
| Follow-up and survivorship | Regular reviews, skin checks, imaging when indicated, lifestyle and psychological support | Monitors recurrence, manages late effects and supports wellbeing |
Referral pathways and how to access care
In Sheffield, patients are usually referred to melanoma services via their GP or a dermatology clinic when a suspicious lesion cannot be managed in primary care or requires specialised assessment. Urgent referral criteria often include lesions with concerning clinical features or those suggestive of locally advanced or metastatic disease. Patients may be seen initially in a dermatology or surgical clinic, where biopsies are taken and staging investigations organised. If melanoma is confirmed, the case may be discussed at a multidisciplinary meeting to agree on the most appropriate management plan within local commissioning arrangements and national guidance.
Diagnosis, staging and treatment planning
Once a melanoma is suspected, diagnosis is confirmed through excision or biopsy with thorough histopathological assessment. Staging is based on tumour thickness, ulceration, mitotic rate, lymph node status and presence of metastases, often using tools such as the American Joint Committee on Cancer (AJCC) staging system. Treatment planning is personalised and may involve wide local excision with safety margins, sentinel lymph node biopsy, nodal dissection, radiotherapy, systemic therapy or a combination. The treatment team reviews all relevant findings and discusses the risks, benefits and follow-up requirements with the patient before proceeding.
Systemic therapies and clinical trials
For patients with advanced or high-risk melanoma, systemic treatments such as immune checkpoint inhibitors or targeted agents directed at specific mutations may be recommended. Decisions around these therapies consider tumour characteristics, patient fitness, comorbidities and preferences. Specialist centres in larger hospitals often facilitate access to clinical trials, giving eligible patients the opportunity to participate in studies of new combinations or approaches. Close monitoring during treatment helps manage side effects and ensures timely adjustments when needed.
Follow-up, surveillance and long-term support
After active treatment, structured follow-up is used to monitor for recurrence, manage late effects of therapy and support mental and physical health. The schedule is typically risk-adapted, with higher-risk patients seen more frequently for history, examination and investigations. Many centres provide survivorship plans, lifestyle advice, skin checks and psychological services. Patients are encouraged to report new or changing lesions promptly and to attend scheduled appointments, while clear guidance is provided on when to seek urgent review.
Practical next steps for patients and clinicians
For patients in Sheffield concerned about melanoma, the first step is to discuss findings with a GP or dermatologist, who can arrange an urgent referral if appropriate. Clinicians should ensure referrals include relevant history, examination findings and any available imaging or pathology. It is helpful to verify current pathways with local commissioning arrangements and to check whether specific investigations or trials are available through the regional melanoma service. Clear communication about diagnosis, staging, treatment options and follow-up responsibilities supports coordinated, high-quality care over time.